PCLO.V - PharmaCielo Ltd.
| Previous Close | 3.5000 |
| Open | 3.4600 |
| Bid | 3.5700 x 0 |
| Ask | 3.6200 x 0 |
| Day's Range | 3.4000 - 3.7200 |
| 52 Week Range | 2.5100 - 11.5000 |
| Volume | 137,735 |
| Avg. Volume | 128,553 |
| Market Cap | 341.799M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4210 |
| Earnings Date | Nov. 25, 2019 - Dec. 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.40 |
CNW GroupPharmaCielo Announces RSU Grant
TORONTO , Nov. 8, 2019 /CNW/ - PharmaCielo Ltd. (" PharmaCielo " or the " Company ") ( TSXV:PCLO, OTC:PHCEF ) today announced that on November 5, 2019 (the " Grant Date ") ...
- CNW Group
IIROC Trading Resumption - PCLO
VANCOUVER , Nov. 6, 2019 /CNW/ - Trading resumes in: Company: Pharmacielo Ltd. TSX-Venture Symbol: PCLO Resumption (ET): 09:30 AM IIROC can make a decision to impose a temporary suspension (halt) of trading ...
CNW GroupPharmaCielo Announces Termination of Scheme Implementation Agreement with Creso Pharma
TORONTO, Nov. 5, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF) announces that earlier today it was advised by Creso Pharma Limited ("Creso Pharma") that due to BDO Corporate Finance (WA) Pty Ltd. changing its independent expert report to conclude that the PharmaCielo Share Scheme is neither fair nor reasonable and is not in the best interests of shareholders of Creso Pharma, it is impossible for the Board of Directors of Creso Pharma to support the Share and Option Schemes (the "Schemes") in their current form. As a result of the Creso Pharma Board of Directors changing its recommendation in respect of the Schemes, PharmaCielo has terminated the Scheme Implementation Agreement (the "Scheme Implementation Agreement"), originally announced on June 6, 2019, in accordance with its terms.
- CNW Group
PharmaCielo Trading Halted Pending Update from Creso Pharma
TORONTO, Nov. 4, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), today announced that trading in its common shares was halted today, pending an update from Creso Pharma Limited ("Creso Pharma") in respect of PharmaCielo's proposed acquisition of the company, which was originally announced on June 6, 2019. As outlined in a press release on November 1, 2019, BDO Corporate Finance (WA) Pty Ltd. has updated its independent expert report dated September 26, 2019, to conclude that the Share Scheme of Arrangement (the "Share Scheme") under which PharmaCielo has proposed to acquire all of the issued and outstanding shares of Creso Pharma, is neither fair nor reasonable and is not in the best interests of shareholders of Creso Pharma. PharmaCielo has sought confirmation from the Board of Directors of Creso Pharma that it continues to support the Share Scheme, the option scheme and the other transactions contemplated by the Scheme Implementation Agreement originally announced on June 6, 2019, and is still awaiting a response.
- CNW Group
IIROC Trading Halt - PCLO
VANCOUVER , Nov. 4, 2019 /CNW/ - The following issues have been halted by IIROC: Company: Pharmacielo Ltd. TSX-Venture Symbol: PCLO (All issues) Reason: Pending News Halt Time (ET): 9:18:16 AM IIROC ...
CNW GroupPharmaCielo Provides Update on Proposed Acquisition of Creso Pharma
TORONTO, Nov. 1, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), today announced that in respect of its proposed acquisition of Creso Pharma Limited ("Creso Pharma") originally announced on June 6, 2019, and prior to the opening of the markets this morning, the Company was advised that Creso Pharma had received a supplementary independent expert report from BDO Corporate Finance (WA) Pty Ltd. updating its September 26, 2019 report, to now conclude that the Share Scheme of Arrangement (the "Share Scheme") under which PharmaCielo has proposed to acquire all of the issued and outstanding shares of Creso Pharma, is neither fair nor reasonable and is not in the best interests of shareholders of Creso Pharma. The PharmaCielo Board of Directors has communicated that while it remains committed to closing the proposed transaction with Creso Pharma in its current form and in a disciplined manner, it will not increase the consideration that has been offered to Creso Pharma shareholders and listed optionholders as part of the acquisition.
CNW GroupPharmaCielo Announces Creso Pharma's Receipt of Australian Court Approval to Convene Meeting of Shareholders
PharmaCielo's acquisition of Creso Pharma will establish a global medicinal cannabis company, positioned to rapidly develop new markets and grow sales in the expanded footprint served by the combined company. TORONTO, Oct. 2, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), is pleased to announce key developments in respect of its friendly acquisition of Australian Securities Exchange ("ASX") listed Creso Pharma Limited ("Creso Pharma") originally announced on June 6, 2019. Creso Pharma has informed the Company that it has received approval from the Supreme Court of Western Australia (the "Court") to convene meetings of its shareholders and listed optionholders (the "Meetings"), and if thought fit, to approve the Schemes of Arrangement whereby PharmaCielo would acquire all of the issued and outstanding shares and listed options of Creso Pharma (the "Schemes of Arrangement").
CNW GroupHorizons ETFs Rebalances Marijuana-Focused Index ETF Suite
Horizons ETFs maintains the world's largest suite of cannabis ETFs TORONTO , Sept. 27, 2019 /CNW/ - Horizons ETFs Management (Canada ) Inc. (" Horizons ETFs ") has completed the quarterly rebalance ...
- Baystreet
Stocks in play: PharmaCielo Ltd.
Has signed a United States sales agreement with an established multi-state distributor, General Extract ...
CNW GroupPharmaCielo Enters the U.S. with $3 Million Q4 Sales Agreement and Completes Introductory Shipments to Multi-state Distributor General Extract LLC
2019 market introduction revenues projected at minimum $3 million CDN Agreement covers sales and distribution of medicinal CBD isolate in multiple US states commencing in 2019 with allowance for renewal ...
- The Motley Fool
1 Newly Listed Weed Stock Could Bring You Riches
If you want to bet on a cannabis IPO that could earn you a fortune in the future, PharmaCielo Ltd. (TSXV:PCLO) is a sound choice. This premier cultivator of medicinal-grade cannabis has all the right elements to prosper in the highly competitive cannabis industry.
CNW GroupPharmaCielo Announces Financial Results for the Second Quarter 2019
Well capitalized with a cash and short-term investments of $33.2 million as of June 30, 2019 Subsequent to quarter completed first commercial export of CBD from Colombia to Europe Have cleared all regulatory ...
CNW GroupPharmaCielo's Very First Commercial CBD Export from Colombia Lands in Europe
TORONTO and CHAM, Switzerland, Aug. 19, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., confirmed today it successfully completed the first commercial export of CBD isolate to Europe. The inaugural shipment of the high quality CBD isolate, a key ingredient in various cannabis derived therapeutic, nutraceutical, topicals and lifestyle products, was delivered to the Swiss headquarters of Creso Pharma, a global pharmaceutical with expertise in cannabis- and hemp-derived products for human and veterinarian use.
CNW GroupPharmaCielo Expands Further Into Latin America With Sales Agreement to Supply CBD Extracts, Oils and Veterinary Products to Laboratorios Adler
TORONTO and MONTEVIDEO, Uruguay, Aug. 13, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced it has signed a sales agreement with Uruguay-based Laboratorios Adler ("Adler"). According to the agreement, PharmaCielo will provide Adler with bulk CBD extracts, bulk and bottled CBD oils and veterinary products that will be sold by Adler in Uruguay, Paraguay, Bolivia and Southern Brazil.
CNW GroupPharmaCielo Joins Canadian Market Cannabis Tracking and Verification Initiative
TORONTO and RIONEGRO, Colombia, Aug. 8, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced it has joined the TruTrace Technologies, Inc. ("TruTrace") (CSE:TTT, OTCQB:TTTSF) and Shoppers Drug Mart initiated medical cannabis pilot verification program ("Pilot Program").
- The Motley Fool
Latest Developments Highlight Why It’s Time to Buy PharmaCielo (TSXV:PCLO)
Get ready for PharmaCielo Ltd. (TSXV:PCLO) to soar as commercial production nears.
CNW GroupPharmaCielo Colombia Holdings S.A.S. Appoints New and Diversified Board of Directors
New board consists of diversified experts with domestic and international business, academia, agriculture, trade and healthcare expertise Half of new board members are businesswomen, reflecting the overall ...
CNW GroupPharmaCielo Achieves Twelvefold Increase in Dried Cannabis Processing Capacity to Meet Global Demand for Medicinal Oil Extracts
TORONTO and RIONEGRO, Colombia, Aug. 1, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., is ramping up its oil processing capabilities in the Company's Rionegro, Colombia facility following the recent acquisition and installation of additional high-performance, high-volume extractors, combined with proprietary extraction techniques.
- Market Exclusive
PharmaCielo to Begin Export of CBD Extracts from Colombia
PharmaCielo Ltd. (TSXV: PCLO) (OTC: PHCEF), the Canadian parent of Colombia's cultivator and producer of medicinal-grade cannabis extracts PharmaCielo Colombia Holdings S.A.S., announced that it has completed the necessary permitting process required to enable Colombia's first commercial export and sale of non-psychoactive (CBD) isolate. The process fulfills the extensive and final regulatory obligations required, including […]The post PharmaCielo to Begin Export of CBD Extracts from Colombia appeared first on Market Exclusive.
- Market Exclusive
Cannabis Stock News Daily Roundup July 29
iAnthus Capital Holdings (CSE: IAN) (OTCQX: ITHUF) has reported several recent milestones in Massachusetts. The company’s Mayflower Medicinals was approved for a retail marijuana license by the City of Worcester License Commission to operate an adult-use dispensary. The company's medical marijuana cultivation and processing facility in Holliston is supplying flower, pre-rolls, distillate, and edibles to Mayflower’s […]The post Cannabis Stock News Daily Roundup July 29 appeared first on Market Exclusive.
CNW GroupPharmaCielo Completes Acquisition of Ubiquo Telemedicina
TORONTO, July 26, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced that it has completed the acquisition of all of the shares (the "Acquisition") of Ubiquo Telemedicina S.A.S. ("Ubiquo Telemedicina"), previously announced on April 20, 2018.
CNW GroupPharmaCielo First to Receive Colombian Government Export Approval for Commercial Sale of CBD Isolate
Completion of commercial export permit process clears the way for PharmaCielo to initiate shipment of its medicinal-grade CBD extracts to wholesale distributors and product manufacturers CBD isolate to ...
CNW GroupPharmaCielo Colombia Holdings S.A.S. Appoints Andres Felipe Botero as Chief Operations Officer
RIONEGRO, Colombia, July 22, 2019 /CNW/ - PharmaCielo Colombia Holdings S.A.S. ("PharmaCielo Colombia" or the "Company"), the premier cultivator and producer of medicinal-grade cannabis oils and extracts in Colombia and subsidiary of Canadian firm PharmaCielo Ltd. (TSXV:PCLO, OTC:PHCEF), is pleased to announce the appointment of Andres Felipe Botero as Chief Operations Officer (COO).
